此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Ublituximab 在复发性多发性硬化症参与者中的扩展研究

2026年10月28日 更新者:TG Therapeutics, Inc.

Ublituximab 在复发性多发性硬化症受试者中的开放标签扩展研究

The purpose of this study is to evaluate long-term safety and efficacy of ublituximab therapy in participants with relapsing multiple sclerosis (RMS).

研究概览

地位

主动,不招人

详细说明

TG1101-RMS303 is an open-label, single-arm extension study designed to evaluate long-term safety and efficacy of ublituximab in participants with RMS. Participants who complete the 96-week, double-blind treatment period of TG1101-RMS301 (RMS301 [NCT03277261]) or TG1101-RMS302 (RMS302 [NCT03277248]) are eligible for participation in this Open Label Extension (OLE) study. Participants may also be eligible for TG1101-RMS303 if they have completed Week 208 of TG1101-RMS201E (RMS201E [NCT03381170]) (United States of America [USA] participants only).

研究类型

介入性

注册 (估计的)

1100

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Cherkasy、乌克兰、18009
        • TG Therapeutics Investigational Trial Site
      • Chernihiv、乌克兰、14001
        • TG Therapeutics Investigational Trial Site
      • Chernihiv、乌克兰、14029
        • TG Therapeutics Investigational Trial Site
      • Chernivtsi、乌克兰、58002
        • TG Therapeutics Investigational Trial Site
      • Ivano-Frankivsk、乌克兰、76008
        • TG Therapeutics Investigational Trial Site
      • Kharkiv、乌克兰、61058
        • TG Therapeutics Investigational Trial Site
      • Kharkiv、乌克兰、61103
        • TG Therapeutics Investigational Trial Site
      • Kharkiv、乌克兰、61176
        • TG Therapeutics Investigational Trial Site
      • Kyiv、乌克兰、03037
        • TG Therapeutics Investigational Trial Site
      • Kyiv、乌克兰、03115
        • TG Therapeutics Investigational Trial Site
      • Lviv、乌克兰、79000
        • TG Therapeutics Investigational Trial Site
      • Lviv、乌克兰、79010
        • TG Therapeutics Investigational Trial Site
      • Odesa、乌克兰、65009
        • TG Therapeutics Investigational Trial Site
      • Poltava、乌克兰、36011
        • TG Therapeutics Investigational Trial Site
      • Ternopil、乌克兰、46027
        • TG Therapeutics Investigational Trial Site
      • Uzhhorod、乌克兰、88018
        • TG Therapeutics Investigational Trial Site
      • Vinnytsia、乌克兰、21005
        • TG Therapeutics Investigational Trial Site
      • Zaporizhia、乌克兰、69065
        • TG Therapeutics Investigational Trial Site
      • Zaporizhia、乌克兰、96900
        • TG Therapeutics Investigational Trial Site
      • Zhytomyr、乌克兰、10002
        • TG Therapeutics Investigational Trial Site
      • Tbilisi、乔治亚州、00112
        • TG Therapeutics Investigational Trial Site
      • Tbilisi、乔治亚州、00114
        • TG Therapeutics Investigational Trial Site
      • Tbilisi、乔治亚州、00159
        • TG Therapeutics Investigational Trial Site
      • Tbilisi、乔治亚州、00160
        • TG Therapeutics Investigational Trial Site
      • Tbilisi、乔治亚州、00172
        • TG Therapeutics Investigational Trial Site
      • Tbilisi、乔治亚州、00179
        • TG Therapeutics Investigational Trial Site
      • Arkhangelsk、俄罗斯、163045
        • TG Therapeutics Investigational Trial Site
      • Barnaul、俄罗斯、656045
        • TG Therapeutics Investigational Trial Site
      • Bryansk、俄罗斯、241033
        • TG Therapeutics Investigational Trial Site
      • Chelyabinsk、俄罗斯、454021
        • TG Therapeutics Investigational Trial Site
      • Kemerovo、俄罗斯、650066
        • TG Therapeutics Investigational Trial Site
      • Krasnoyarsk、俄罗斯、660037
        • TG Therapeutics Investigational Trial Site
      • Kursk、俄罗斯、305007
        • TG Therapeutics Investigational Trial Site
      • Moscow、俄罗斯、125367
        • TG Therapeutics Investigational Trial Site
      • Moscow、俄罗斯、127015
        • TG Therapeutics Investigational Trial Site
      • Nizhny Novgorod、俄罗斯、603155
        • TG Therapeutics Investigational Trial Site
      • Novosibirsk、俄罗斯、630007
        • TG Therapeutics Investigational Trial Site
      • Novosibirsk、俄罗斯、630087
        • TG Therapeutics Investigational Trial Site
      • Pyatigorsk、俄罗斯、357538
        • TG Therapeutics Investigational Trial Site
      • Saint Petersburg、俄罗斯、197002
        • TG Therapeutics Investigational Trial Site
      • Saint Petersburg、俄罗斯、197110
        • TG Therapeutics Investigational Trial Site
      • Saint Petersburg、俄罗斯、197376
        • TG Therapeutics Investigational Trial Site
      • Saransk、俄罗斯、430032
        • TG Therapeutics Investigational Trial Site
      • Smolensk、俄罗斯、214018
        • TG Therapeutics Investigational Trial Site
      • Tomsk、俄罗斯、634050
        • TG Therapeutics Investigational Trial Site
      • Tyumen、俄罗斯、625000
        • TG Therapeutics Investigational Trial Site
      • Ufa、俄罗斯、450005
        • TG Therapeutics Investigational Trial Site
      • Yekaterinburg、俄罗斯、620102
        • TG Therapeutics Investigational Trial Site
      • Osijek、克罗地亚、31000
        • TG Therapeutics Investigational Trial Site
      • Varaždin、克罗地亚、42000
        • TG Therapeutics Investigational Trial Site
      • Zagreb、克罗地亚、10000
        • TG Investigational Trial Site
      • Belgrade、塞尔维亚、11000
        • TG Therapeutics Investigational Trial Site
      • Kragujevac、塞尔维亚、34000
        • TG Therapeutics Investigational Trial Site
      • Katowice、波兰、40-555
        • TG Therapeutics Investigational Trial Site
      • Katowice、波兰、40-568
        • TG Therapeutics Investigational Trial Site
      • Katowice、波兰、40-684
        • TG Therapeutics Investigational Trial Site
      • Krakow、波兰、31-505
        • TG Therapeutics Investigational Trial Site
      • Lodz、波兰、41-800
        • TG Therapeutics Investigational Trial Site
      • Olsztyn、波兰、10-561
        • TG Therapeutics Investigational Trial Site
      • Poznan、波兰、61-583
        • TG Therapeutics Investigational Trial Site
      • Warsaw、波兰、04-141
        • TG Therapeutics Investigational Trial Site
      • Zabrze、波兰、04-749
        • TG Therapeutics Investigational Trial Site
      • Grodno、白俄罗斯、230017
        • TG Therapeutics Investigational Trial Site
      • Grodno、白俄罗斯、320017
        • TG Therapeutics Investigational Trial Site
      • Minsk、白俄罗斯、220114
        • TG Therapeutics Investigational Trial Site
      • Minsk、白俄罗斯、220116
        • TG Therapeutics Investigational Trial Site
      • Minsk、白俄罗斯、220226
        • TG Therapeutics Investigational Trial Site
    • California
      • Pasadena、California、美国、91105
        • TG Therapeutics Investigational Trial Site
    • Colorado
      • Denver、Colorado、美国、80045
        • TG Therapeutics Investigational Trial Site
    • Florida
      • Miami、Florida、美国、33136
        • TG Therapeutics Investigational Trial Site
      • Tampa、Florida、美国、33612
        • TG Therapeutics Investigational Trial Site
    • Illinois
      • Northbrook、Illinois、美国、60062
        • TG Therapeutics Investigational Trial Site
    • Kansas
      • Kansas City、Kansas、美国、66160
        • TG Therapeutics Investigational Trial Site
    • Michigan
      • Detroit、Michigan、美国、48201
        • TG Therapeutics Investigational Trial Site
    • Nevada
      • Las Vegas、Nevada、美国、89106
        • TG Therapeutics Investigational Trial Site
    • New Jersey
      • Teaneck、New Jersey、美国、07666
        • TG Therapeutics Investigational Trial Site
    • New Mexico
      • Albuquerque、New Mexico、美国、87131
        • TG Therapeutics Investigational Trial Site
    • New York
      • Amherst、New York、美国、14266
        • TG Therapeutics Investigational Trial Site
    • Ohio
      • Columbus、Ohio、美国、43214
        • TG Therapeutics Investigational Trial Site
      • Westerville、Ohio、美国、43081
        • TG Therapeutics Investigational Trial Site
    • Tennessee
      • Knoxville、Tennessee、美国、37922
        • TG Therapeutics Investigational Trial Site
    • Texas
      • Dallas、Texas、美国、75246
        • TG Therapeutics Investigational Trial Site
      • Frisco、Texas、美国、75034
        • TG Therapeutics Investigational Trial Site
      • Round Rock、Texas、美国、78681
        • TG Therapeutics Investigational Trial Site
      • San Antonio、Texas、美国、78258
        • TG Therapeutics Investigational Trial Site
    • Washington
      • Seattle、Washington、美国、98109
        • TG Therapeutics Investigational Trial Site

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

Participants must meet the following criteria:

  1. Complete the 96-week double-blind TG1101-RMS301 (NCT03277261) or TG1101-RMS302 (NCT03277248) study or complete the final Week 208 visit of the TG1101-RMS201E (NCT03381170) study
  2. Investigator believes may benefit from treatment with ublituximab
  3. Are able and willing to provide written informed consent (e.g., before the first infusion) and to comply with the study protocol
  4. Female participants of child-bearing potential, and male partners must consent to use a medically acceptable method of contraception from consent, throughout the study period, and for 20 weeks after the last dose of ublituximab

Exclusion Criteria:

Participants who meet any of the following exclusion criteria are not to be enrolled to this study:

  1. Any significant or uncontrolled medical condition or treatment-emergent, clinically significant laboratory abnormality such as:

    1. Absolute neutrophil count < 1.5 x 10e3/µL
    2. Hematocrit < 24%
    3. Platelet count < 150,000 cell/mm^3
    4. Hypogammaglobulinemia immunoglobulin G (IgG) < 4.0g/L
  2. Active infection

  3. Ongoing pregnancy (female participants)

  4. Participants who discontinued ublituximab treatment or withdrew consent from the TG1101-RMS301 or TG1101-RMS302 study during the 96-week evaluation period or prior to completing the final Week 208 visit of the TG1101-RMS201E study

  5. Participants who have started any disease modifying therapy (DMT), stem cell transplantation, or participation in any other interventional clinical trial after completion of the 96-week visit in the TG1101-RMS301, TG1101-RMS302, or after completing the final Week 208 visit of the TG1101-RMS201E study

  6. Participants who have had a confirmed multiple sclerosis (MS) relapse within the past 30 days prior to Week 1 Day 1 (W1D1). Following a relapse, participants must be neurologically stable for at least 30 days prior to screening or W1D1 of the OLE

  7. Participants with unstable disease activity

  8. Presence of malignancy, except for surgically excised basal or squamous cell skin lesions

  9. Vaccination with live virus within 2 months of randomization

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Ublituximab Infusions

RMS301/RMS302: All participants transferring from RMS301/RMS302 who sign consent for this study will receive an initial 4-hour infusion of 150 mg ublituximab on Week 1 (Day 1) followed by a 1-hour infusion of 450 mg ublituximab 14 days later Week 3 (Day 15). Subsequent infusions of ublituximab will be administered at 450 mg for 1-hour every 24 weeks from Weeks 24 to 312.

RMS201E: All participants transferring from RMS201E who sign consent for this study will receive a 1-hour infusion of 450 mg ublituximab on Week 1 (Day 1) and subsequent infusions of ublituximab will be administered at 450 mg for 1-hour every 24 weeks from Weeks 24 to 312.

For all participants (RMS301/RMS302/RMS201E), infusion treatment will continue for 312 weeks, or until physician or participant decision to withdraw from the study.

Ublituximab (TG-1101) is a recombinant chimeric monoclonal antibody targeting CD20, available as a 25 mg/mL concentrate for intravenous use, supplied by TG Therapeutics, Inc.

其他名称:
  • TG-1101

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Annualized Relapse Rate (ARR)
大体时间:Up to Week 336

ARR is defined as the number of relapses per-participant year. The estimate of ARR will be the total number of relapses divided by the sum of duration on study treatment (years).

Up to Week 336

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2019年11月18日

初级完成 (估计的)

2032年5月31日

研究完成 (估计的)

2032年5月31日

研究注册日期

首次提交

2019年10月16日

首先提交符合 QC 标准的

2019年10月16日

首次发布 (实际的)

2019年10月18日

研究记录更新

最后更新发布 (实际的)

2026年10月30日

上次提交的符合 QC 标准的更新

2026年10月28日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • TG1101-RMS303
  • 2019-003625-16 (EudraCT编号)
  • 2019 (美国 NIH 拨款/合同)

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅